We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AYTU BioPharma Inc | NASDAQ:AYTU | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0001 | 0.00% | 3.0501 | 3.05 | 3.18 | 3.18 | 3.07 | 3.07 | 6,093 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
| |||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 11, 2023 the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Aytu BioPharma, Inc. (“Aytu” or the “Company”) approved the following bonus for the Named Executive Officers (“NEOs”):
Name |
| Title |
| Bonus Amount |
| % of Target |
|
Joshua R. Disbrow | Chief Executive Officer | $118,000 | 33% | ||||
Mark K. Oki | Chief Financial Officer & Secretary | $ 83,000 | 50% |
The bonuses earned by Mr. Disbrow and Mr. Oki will be paid in January 2024. If Mr. Disbrow or Mr. Oki’s employment terminates prior to January 2024, the approved bonus will be paid in full.
Document and Entity Information |
Aug. 11, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Aug. 11, 2023 |
Entity File Number | 001-38247 |
Entity Registrant Name | AYTU BIOPHARMA, INC. |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 47-0883144 |
Entity Address, Address Line One | 373 Inverness Parkway |
Entity Address, Adress Line Two | Suite 206 |
Entity Address, City or Town | Englewood |
Entity Address, State or Province | CO |
Entity Address, Postal Zip Code | 80112 |
City Area Code | 720 |
Local Phone Number | 437-6580 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0001 per share |
Trading Symbol | AYTU |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001385818 |
Amendment Flag | false |
1 Year AYTU BioPharma Chart |
1 Month AYTU BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions